Letter to the EditorMolnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase☆
Cited by (0)
- ☆
Eric Yuk Fai Wan, Boyuan Wang, and Sukriti Mathur are co-first authors and contributed equally.
© 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.